A story about InKine Pharmaceutical Co. in BioWorld Today, Nov. 12, 1997, should have said the company raised $17 million in a private financing, with initial closing on $15.6 million of that amount. The company also plans to enroll 100 patients in a Phase III trial of CBP-1011.

In an article on infertility in BioWorld Today, Nov. 12, 1997, the last sentence of the second paragraph should have read: That works out at about 400 fully developed ova in a lifetime — one in 5,000 of her 2 million original investment at birth.